SCHEMBL22472801

SCHEMBL22472801

CCCCCOc1ccc(CCNC(=O)c2ncn3ccc(C)nc23)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.48
RAB9A P51151 3/20 0.48
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
ALDH1A1 P00352 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.43
MAPT P10636 3/20 0.43
ACACB O00763 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
CNR2 P34972 3/20 0.42
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
TAS1R2 Q8TE23 1/20 0.41
S1PR2 O95136 2/20 0.40
S1PR1 P21453 2/20 0.40
S1PR3 Q99500 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22472799 0.90 SMN1; SMN2 (0.47) NPC1RAB9ASMN1; SMN2MAPTMAPK1
SCHEMBL25581322 0.84 NPC1 (0.47) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL25581632 0.82 PPARA (0.36) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL22472777 0.80 NPC1 (0.49) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL25581688 0.80 SMN1; SMN2 (0.34) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL22472791 0.79 ACACB (0.39) SMN1; SMN2ACACBLMNATP53
SCHEMBL22472792 0.76 ADORA2A (0.42) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL22472803 0.76 USP28 (0.40) NPC1RAB9AKMT2AALDH1A1MAPT
SCHEMBL22472750 0.74 SMN1; SMN2 (0.47) SMN1; SMN2S1PR2S1PR1S1PR3LPAR2
SCHEMBL22472796 0.73 FAAH (0.46) NPC1RAB9ASMN1; SMN2MAPTS1PR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3215510-B1 SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2023-06-07 EP disclosed
US-10786508-B2 Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders LYSOSOMAL THERAPEUTICS INC. (US) 2020-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10786508-B2 Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders GBA1, GAA, SNCA NPC1 823/4885RAB9A 1395/4885KMT2A 469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.